医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Fujifilm Completes Acquisition of Shenandoah Biotechnology

2022年03月28日 PM10:08
このエントリーをはてなブックマークに追加


 

TOKYO

FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, completed the acquisition of Shenandoah Biotechnology, Inc., a leading manufacturer of recombinant proteins. Terms of the deal were not disclosed.

Located in Warminster, Pennsylvania, Shenandoah Biotechnology manufactures recombinant proteins including cytokines and growth factors. Shenandoah Biotechnology recently launched their CTG Grade™ line of cytokines and growth factors that are manufactured according to cGMP guidelines in the Company’s new state-of-the-art, ISO 9001:2015 certified facility.

Shenandoah Biotechnology’s portfolio of recombinant proteins complements FUJIFILM Irvine Scientific, Inc.’s advanced cell culture solutions and expertise in bioprocessing, which will provide customers with a single point of access for their life science research, discovery, and cell and gene therapy needs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005469/en/

CONTACT

Lily Jeffery

Zyme Communications

Phone: +44 (0)7891 477 378

Email: lily.jeffery@zymecommunications.com

同じカテゴリーの記事 

  • パース・バイオサイエンシズが研究室用自動化プロバイダー・プログラムをローンチし、ハミルトン、オープントロンズ、ラボワークス、SPTラボテックと提携
  • Parse Biosciences与Hamilton、Opentrons Labworks和SPT Labtech合作推出实验室自动化供应商计划
  • Charting New Paths: Mannatech Expanding with Thailand Office, Grand Opening, September 2024
  • Exergen起诉Baxter International,以捍卫其公布口腔体温计准确性数据的权利
  • Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting